Fundación Hospital Alcorcón -ko ikertzaileekin lankidetzan egindako argitalpenak (12)

2024

  1. Ustekinumab is effective and safe in the long-term treatment of erythrodermic psoriasis: Multicenter study in daily practice

    JEADV Clinical Practice, Vol. 3, Núm. 2, pp. 604-610

2022

  1. Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness

    Expert Opinion on Biological Therapy

2021

  1. Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 9, pp. 817-827

  2. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

    Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517

2020

  1. A retrospective, observational multicenter study of 141 patients treated with ustekinumab 90 mg

    Dermatologic Therapy, Vol. 33, Núm. 4

  2. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

    Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150

  3. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study

    Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741

2018

  1. Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study

    Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800

  2. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis

    Pharmacogenomics Journal, Vol. 18, Núm. 1, pp. 70-75

2015

  1. New immune system genetic polymorphisms associated with moderate-to-severe plaque psoriasis: A case-control study

    British Journal of Dermatology

  2. Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis

    Journal of Immunology Research, Vol. 2015

  3. The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis

    Pharmacogenomics, Vol. 16, Núm. 15, pp. 1723-1731